CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2174-2180

  Zaja, F ^a   Tomadini, V ^a   Zaccaria, A ^b   Lenoci, M ^c   Battista, M ^a   Molinari, A L ^b   Fabbri, A ^c   Battista, R ^d   Cabras, M G ^e   Gallamini, A ^f   Fanin, R ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b Division of Hematology   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d Division of Hematology   (Italy)

^e Division of Hematology   (Italy)

^f Division of Hematology   (Italy)

Author keywords

Cardiotoxicity; Elderly patients; Liposomal doxorubicin; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TROPONIN I; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; INFECTION; LARGE CELL LYMPHOMA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PREDNISONE; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33750492292     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600799946     Document Type: Article

References (22)

1. Miller, B. (1992) Cancer statistics review: 1973-1989, National Cancer Institute NIH Pub No. 92-2789, 17, pp. 1-16.
2. A predictive model for aggressive non-Hodgkin's lymphoma. (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med, 329, pp. 987-994.
3. Coiffier, B and Lepade, E and Brière, J and Herbrecht, R and Tilly, T and Bouabdallah, R and (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med, 346, pp. 235-242.
4. Northfelt, D and Martin, F and Working, P and Volberding, P and Russel, J and Newman, M and (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyetylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J Clin Pharmacol, 36, pp. 55-63.
5. Gabizon, A and Catane, R and Uziely, B and Kaufman, B and Safra, T and Cohen, R and (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyetylene-glycol coated liposomes Cancer Res, 54, pp. 987-992.
6. Bogner, J and Kronawitter, U and Rolinski, B and Truebembach, K and Goebel, F. (1994) Liposomial doxorubicin in the treatment of advanced AIDS related Kaposi sarcoma J Acquir Immune Defic Syndr, 7, pp. 463-468.
7. Harrison, M and Tomlinson, D and Stewart, S. (1995) Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma J Clin Oncol, 13, pp. 914-920.
8. James, N and Coker, R and Tomlinson, D and Harris, J and Gompels, M and Pinching, A and (1994) Liposomal doxorubicin: An effective new treatment for Kaposi's sarcoma in AIDS Clin Oncol, 6, pp. 294-296.
9. Berry, G and Billingham, M and Alderman, E and Richardson, P and Torti, F and Lum, B and (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's Sarcoma patients treated with pegylated liposomal doxorubicin Ann Oncol, 9, pp. 711-716.
10. Wollina, U and Graefe, T and Kaatz, M. (2001) Pegylated doxorubicin for primary cutaneous T-cell lymphoma: A report on ten patients with follow-up J Cancer Res Clin Oncol, 127, pp. 128-134.
11. Aviles, A and Neri, N and Castaneda, C and Talavera, A and Huerta-Guzman, J and Gonzalez, M. (2002) Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma Med Oncol, 19, pp. 55-58.
12. Chanan-Khan, A and Islam, T and Bernstein, S. (2001) CDOP (cyclophosphamide, doxil, vincristine, prednisone) as a front-line regimen for elderly patients with intermediate grade non-Hodgkin's lymphoma (IG-NHL) Blood, 98, pp. 4681a.
13. Martino, R and Perea, G and Caballero, M and Mateos, M and Ribera, J and de Oteyza, J and (2002) Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study Haematologica, 87, pp. 822-827.
14. Tsavaris, N and Kosmas, C and Vadiaka, M and Giannouli, S and Siakantaris, M and Vassilakopoulos, T and (2002) Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma Anticancer Res, 22, pp. 1845-1848.
15. Tulpule, A and Khan, A and Mohrbacher, A. (2004) A phase II trial of pegylated liposomal doxorobucin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non Hodgkin's lymphoma ASCO, 23, pp. 6688a.
16. Harris, N and Jaffe, E and Stein, H and Banks, P and Chan, J and Cleary, M and (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group Blood, 84, pp. 1361-1392.
17. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol, 17, pp. 1244-1253.
18. Kaplan, J and Meier, P. (1958) Non parametic estimation from incomplete observation J Am Stat Assoc, 53, pp. 457-481.
19. Lipshultz, S and Grenier, M and Colan, S. (1999) Doxorubicin-induced cardiomyopathy N Engl J Med, 340, pp. 653-655.
20. Sparano, J and Wolff, A and Brown, D. (2000) Troponins for predicting cardiotoxicity from cancer therapy Lancet, 356, pp. 1947-1948.
21. Auner, H and Tinchon, C and Quehenberger, F and Linkesch, W and Sill, H. (2001) Troponins in prediction of cardiotoxic effects Lancet, 357, pp. 808.
22. Cardinale, D and Sandri, M and Martinoni, A and Tricca, A and Civelli, M and Lamantia, G and (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy J Am Coll Cardiol, 36, pp. 517-522.